Dengue virus NS4A protein dynamics shape how the virus hijacks cells
Official title: Dengue virus NS4A protein dynamics drive membrane deformation
Funded at University of California at Davis · NIH-11453454 · Data updated 2026-11-12
This grant studies how a dengue virus protein (NS4A) helps the virus bend cell membranes, aiming to reveal new ways to stop infection.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | July 9, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $80,500 |
| NIH project number | 1R03AI196215-01A1 |
| Project ID | NIH-11453454 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable at this stage; laboratory studies are the focus, with potential future translation to people affected by dengue.
✕Less likely to help
No direct patient benefit during this basic science phase.
What this research studies
If funded, researchers will investigate how NS4A causes membranes in infected cells to reshape themselves to form viral replication sites. The project uses biochemical and biophysical methods to watch NS4A behavior in model systems that mimic human cells. The findings could point to targets for antiviral drugs that block dengue replication and transmission. This work focuses on understanding a human disease process at the molecular level to inform future therapies.
Why it matters
Potential benefit: Understanding NS4A-driven membrane remodeling could lead to new antiviral strategies against dengue.
How similar studies have gone: Previous work in this area has shown NS4A’s role in membrane remodeling, supporting the relevance of this approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Ahn, Surl-Hee — University of California at Davis
- Study coordinator: Ahn, Surl-Hee
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.